Skip to content

Investment Proceeds at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$59.22M-62.1%
Biohaven logo
BiohavenBHVN
$35M-83.3%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$86.5M-33.9%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$83.8M+29.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
$100.83M
Arrowhead Research logo
Arrowhead ResearchARWR
$115.34M-2.4%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.91B+309%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s investment proceeds?
Rapport Therapeutics, Inc. (RAPP) reported investment proceeds of $58.32M in Q1 2026.
How has Rapport Therapeutics, Inc.'s investment proceeds changed year-over-year?
Rapport Therapeutics, Inc.'s investment proceeds decreased by 9.7% year-over-year, from $64.56M to $58.32M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.